Leukemia stem cells (LSCs) are important source of tyrosine kinase inhibitor (TKI) resistance and disease relapse in chronic myelogenous leukemia (CML).
Introduction
Chronic myelogenous leukemia (CML) arises from hematopoietic stem cells (HSCs) malignantly transformed by the BCR-ABL oncogene. CML generally progresses from a chronic phase (CP) to an accelerated phase (AP), then a stage of blast crisis (BC) (1, 2) . A 10-year clinical follow-up demonstrated that treatment with a tyrosine kinase inhibitor (TKI) imatinib mesylate achieved remission in more than 80% of patients with CP CML and significantly prolonged the event-free survival of CML patients harboring the wild-type BCR-ABL (3). However, acquired resistance to imatinib is a challenge in CML treatment. Point mutations (e.g., T315I, G250E, and E255K/V) in BCR-ABL are major causes of imatinib-resistance (4) . Nilotinib and dasatinib, the second-generation TKIs, can achieve good clinical response in most CML patients harboring most mutant isoforms of BCR-ABL except T315I (5) .
Ponatinib, a third-generation TKI, has been approved for treatment in imatinib-resistant CML patients harboring T315I BCR-ABL despite its potential cardiotoxicity (6, 7) . Thus, acquired mutation resistance to imatinib is becoming a manageable clinical issue with these novel TKIs.
The other mechanisms of resistance to imatinib may include leukemia stem cells (LSCs) or leukemia-initiating cells (8) , and BCR-ABL-independent clones (9) . LSCs, characterized by their capacity for self-renewal, and insensitivity to TKIs, may confer clinical resistance to imatinib and lead to CML relapse. Current evidence supports that LSCs are retained in CML patients with remission induced by TKI treatment (10) , for a potential source of CML recurrence (11) . Identification of novel agents capable of Evidence supports that loss of β-catenin impairs LSCs renewal in vivo, and genetic deletion and pharmacologic inhibition of β-catenin targets LSCs in CML (13, 14) .
Deregulated inflammatory cytokines in leukemic bone marrow (BM) may also affect intrinsic regulators of LSCs; for instance, high levels of tumor necrosis factor α (TNFα) in BM promotes CML LSC survival by activating the NF-κB pathway (15) .
However, whether β-catenin and NF-κB, two common intrinsic regulators of LSCs, have interplay, remains unclear.
The present study aimed to examine the interplay between β-catenin (with its partner FOXM1) (16) and NF-κB, and the effect of its chemical intervention on CML LSCs. We discovered a positive-feedback loop regulation between NF-κB p65 and FOXM1/β-catenin in CML LSCs. Disrupting this loop with niclosamide inhibited survival and self-renewal of CML LSCs in vitro and in vivo.
Materials and Methods

Chemicals, antibodies and plasmids
Niclosamide, Annexin V-FITC, cycloheximide, DMSO, anti-Flag, anti-HA anti-actin and anti-tubulin were from Sigma-Aldrich (Sigma, Shanghai). 
Preparation of whole cell lysates and cytoplasmic and nuclear fractions
Whole cell lysates were prepared in RIPA buffer. Cytoplasmic, mitochondrial
and nuclear extracts were prepared as described previously (17, 22) .
Immunoprecipitation and immunoblotting
Research. Immunoprecipitation (IP) and immunoblotting (IB) were performed as previously reported (16) .
Chromatin immunoprecipitation (ChIP) assay
An amount of 1×10 7 K562 cells was prepared with a ChIP kit (EMD Millipore).
The precipitated DNA complexes were analyzed by real-time quantitative PCR (22) .
The primers were listed in Supplementary Table S1 .
Dual luciferase assay
Dual luciferase assay was followed previously reported (22) . Briefly, cells were transfected with plasmids encoding FOXM1-Luc (0.5 μg), NF-κB-Luc (0.5 μg), pTOPflash (0.5 μg), pFOPflash (0.5 μg) and pEFRenilla-Luc (10 ng) with Lipofectamine 2000. Luciferase activity was measured with dual-luciferase assay kit (Promega, Madison, WI) as previously described (22) . The luciferase activity was normalized to Renilla luciferase activity.
Immunofluorescence staining
Cells treated with or without niclosamide for 24 h followed by stimulation of TNFα or WNT3A were collected and cytospan to slides. Immunofluorescence staining was performed as previously described (22) .
In vivo ubiquitination assay
Research. for the last 6 h. In vivo ubiquitination assay was performed as previously reported (21) .
Primary cells
Normal BM samples (n=4) were obtained from healthy donors at the first affiliated hospital of Sun Yat-sen University. CML samples (n=9) were obtained from the first affiliated hospital of Sun Yat-sen University and Guangdong General Hospital. All patients and healthy donors gave their signed informed consent. The study approved by our institute was followed the Declaration of Helsinki principles. The clinical information of CML patients was described in Supplementary Table S2 .
Flow cytometry analysis of intracellular active β-catenin, FOXM1 and p65
The staining procedure was described previously (22) . Samples were analyzed by Accuri C6 (BD Bioscience, San Jose, CA) flow cytometry.
Apoptosis analysis of quiescent cells
The apoptosis of quiescent cells was analyzed according to the previous report (25 CD11B-PE, CD19-APC, and CD3-Alexa Fluo700 (27, 28) .
Retroviral BCR-ABL-driven CML mouse model and treatment
The retroviral construct MSCR-IRES-BCR-ABL-WT-EGFP was used to generate high-titer helper-free retrovirus by transient transfection of Plat-E cells as previously reported (27 
Real-time quantitative PCR
The qPCR experiments were carried out as described previously (22) . The primers were listed in Supplementary Table S1 . 13 
Analysis of leukemia stem cell frequency
Statistical analysis
GraphPad Prism 5.0 (GraphPad Prism Software, San Diego, CA) was used for statistical analysis. All experiments were carried out at least three times, and results were presented as mean ± SEM unless otherwise stated. Comparison between 2 groups was analyzed by t test and between more than 2 groups by one-way ANOVA with post hoc comparison by Tukey test. P < 0.05 was considered statistically significant.
Results
NF-κB physically interacts with FOXM1 and promotes transcription of FOXM1 gene
To examine the potential interaction between NF-κB and FOXM1, 293T cells were co-transfected with HA-tagged p65 and Flag-tagged FOXM1 and subjected to IP analysis. IB analysis revealed FOXM1 presented in anti-p65 IP pellets (Fig. 1A, left) and p65 in anti-FOXM1 IP pellets (Fig. 1A, right) . Moreover, reciprocal co-IP experiments revealed physical interaction of endogenous p65 and FOXM1 proteins in CML cells (Fig. 1B) . Our results suggest that NF-κB protein physically interacts with FOXM1 protein.
We next explored whether transcription factor p65 promotes FOXM1 expression.
IB analysis indicated increased level of endogenous FOXM1 protein with increasing amount of plasmids encoding full-length p65 (Fig. 1C, top) . In a parallel set of experiments cotransfecting a construct containing FOXM1 promoter-driven luciferase (Fig. 1C, bottom) . In contrast, transfection of constructs of truncate p65 (a.a.
1-286) lacking the TAD domain (19) , and truncate p65 (a.a. 286-551) containing NLS and C-terminal domains did not elicit an increase in endogenous FOXM1 protein ( Fig.   1D ), as well as in transcriptional activity of the Luc-FOXM1 promoter (Fig. 1E ).
These data suggest that the C-terminal portion including the NLS appears to be required for promotion of FOXM1 transcription.
NF-κB directly binds FOXM1 gene promoter
We next examined whether cellular endogenous p65 directly bound to the promoter sequence of FOXM1 gene by using chromatin immunoprecipitation (ChIP) assay. Fragmented chromatin of K562 cell lysates was immunoprecipitated with anti-p65 antibody, and specific primers were used to amplify p65 binding sites in the FOXM1 promoter region. The results showed recruitment of endogenous p65 to the FOXM1 gene promoter but not CDS and intron regions of FOXM1 and irrelevant gene GAPDH promoter in CML cells (Fig. 1F) .
Silencing p65 attenuates FOXM1 and β-catenin expression
We next investigated whether NF-κB was required for FOXM1 expression. K562 cells were transfected with siRNA duplexes against RELA gene, and cell lysates were then subjected to IB and luciferase activity assay. Silencing 
NF-κB activation is required for nuclear translocation of FOXM1 and β-catenin
To further delineate the regulation of FOXM1 by canonical activation of NF-κB, K562 cells with p65 silenced by siRNA were exposed to TNFα for different durations.
Control siRNA-treated cells showed TNFα-upregulated FOXM1 expression, which was abrogated in p65 siRNA-treated cells ( Supplementary Fig. S1B ). These data suggest that TNFα upregulates FOXM1 in a p65-dependent manner. Furthermore, p65-deficient MEF cells showed higher turnover rate of FOXM1 compared with MEF p65 +/+ cells ( Supplementary Fig. S1C ).
To better clarify the relationship of p65 and FOXM1, MEF cells harboring p65
or p65 -/-were stimulated by TNFα for various durations, nuclear and cytosolic fractions were examined by IB. The purity of nuclear and cytosol fractions was first verified (Fig. 1G ). In MEF p65 +/+ cells, TNFα stimulation triggered FOXM1 nuclear translocation, coupled with p65 nuclear translocation (Fig. 1H) . In stark contrast,
Research. 16 TNFα stimulation did not trigger nuclear translocation of FOXM1 in MEF p65 -/-cells (Fig. 1H) . A similar effect of TNFα treatment on nuclear relocation of FOXM1 and p65 was observed by confocal fluorescence microscopy (Fig. 1I) . Moreover, WNT3A
stimulation triggered concomitant nuclear translocation of β-catenin and FOXM1
protein in MEF p65 +/+ cells but not MEF p65 -/-cells ( Supplementary Fig. S1D ). These results suggest that p65 is required for FOXM1 nuclear translocation.
Because niclosamide is capable of blocking the canonical activation of NF-κB pathway (17) , K562 cells pretreated with or without niclosamide were exposed to TNFα. IB examination showed that in the absence of niclosamide, IκBα was phosphorylated shortly after TNFα stimulation (Fig. 1J, left) . Accordingly, p65 level was decreased in the cytosolic fraction and increased in the nuclear fraction (Fig. 1J,   left ). Of note, FOXM1 and β-catenin levels were concomitantly decreased in the cytosolic fraction and increased in the nuclear fraction with the change in p65 level (Fig. 1J, left) . Niclosamide completely abolished TNFα-induced nuclear translocation of p65, FOXM1 and β-catenin (Fig. 1J, right) .
Similarly, immunofluorescence staining revealed coupled nuclear translocation of p65 and FOXM1, and p65 and β-catenin in K562 cells with TNFα treatment (Supplementary Fig. S1E and F), which suggests that pharmacological inactivation of NF-κB by niclosamide abrogates nuclear translocation of FOXM1 and β-catenin in CML cells.
FOXM1 and β-catenin positively regulate NF-κB
Research. 17 We next examined whether FOXM1 and β-catenin affected NF-κB level. 293T cells were transfected with plasmids encoding human FOXM1 or β-catenin, and p65 level was assessed by IB. Ectopic expression of FOXM1 and β-catenin increased endogenous p65 level ( Fig. 2A) .
WNT/β-catenin activation promotes nuclear translocation of p65
We determined the effect of WNT/β-catenin activation by WNT3A on p65 level in K562 cells. IB analysis of K562 cells exposed to WNT3A revealed that β-catenin and FOXM1 levels were progressively decreased over time in the cytosolic fraction and progressively increased in the nuclear fraction (Fig. 2B) , which supports nuclear translocation of β-catenin during canonical activation of WNT/β-catenin pathway. IB results showed a coupled and concurrent change of p65 with β-catenin in the cytosolic and nuclear fractions in WNT3A-treated cells (Fig. 2B) , WNT/β-catenin activation promoted the nuclear translocation of p65.
Knockdown of β-catenin and FOXM1 downregulates p65 protein and NF-κB-dependent reporter activity
In K562 cells transfected by two independent siRNA duplexes against human FOXM1, the protein levels of p65 and β-catenin were reduced along with FOXM1 knockdown (Fig. 2C) . Accordingly, NF-κB-and β-catenin-dependent reporter gene transcription was reduced (Fig. 2C) . Similarly, silencing β-catenin by siRNA in K562 cells reduced p65 protein level and NF-κB-dependent reporter gene transcription ( (Fig. 2D) . Collectively, these data suggest a positive-feedback regulation in expression between NF-κB and FOXM1/β-catenin.
Niclosamide induces ubiquitin-mediated degradation of β-catenin protein
Because niclosamide is capable of blocking canonical activation pathways of NF-κB as well as WNT/β-catenin (17), we determined whether niclosamide disturbed the regulatory loop between NF-κB and FOXM1/β-catenin. Niclosamide dose-dependently reduced β-catenin protein level in CML cells (Fig. 2E) . Furthermore, in vivo ubiquitination assay showed that the ubiquitination of β-catenin was increased with niclosamide treatment (Supplementary Fig. S2A ), which suggests that niclosamide induces ubiquitin-proteosome-dependent degradation of β-catenin.
Furthermore, immunofluoresence staining experiments revealed that niclosamide completely abrogated β-catenin nuclear translocation in K562 cells stimulated with WNT3A ( Fig. 2F and Supplementary Fig. S2B ). Concomitantly, the nuclear 
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Because TNFα supports the survival of CML stem/progenitor cells by promoting NF-κB pathway activity (15) , and β-catenin is essential for stemness maintenance of CML LSCs (14), we examined whether the regulatory loop between NF-κB and FOXM1/β-catenin existed in the primary CD34 + cell populations from CML patients.
Purified CD34 + cells from CML patients were labeled with antibodies against p65, FOXM1 and active-β-catenin, then underwent flow cytometry analysis. The results
showed that the levels of intracellular p65, FOXM1 and active-β-catenin were significantly higher in CML CD34 + cells than those in normal BM (NBM) CD34 + cells (Fig. 3A) . Immunofluorescence detection revealed that p65, FOXM1 and β-catenin appeared predominantly distributed in nucleus of the CML CD34 + cells versus NBM counterparts (Supplementary Fig. S3 ). Additionally, overlay between p65 and β-catenin under immunofluorescence observation implied interplay of NF-κB and FOXM1/β-catenin pathways in the primary CML CD34 + cells ( Supplementary   Fig. S3 ).
In order to validate the above implications, primary CD34 + cells from CML patients were co-transfected with constructs of p65 or β-catenin with constructs of Luc-FOXM1 promoter and pEFRRenilla-Luc. The results showed that either p65 or β-catenin significantly increased the transcription of FOXM1 in primary CML CD34 + cells (Fig. 3B, left) . Moreover, co-transfection of constructs of pTOPflash (or pFOPflash) and pEFRRenilla-Luc in combination with p65 or FOXM1 demonstrated that either p65 or β-catenin remarkably increased the TCF/LEF-dependent transcription in primary CML CD34 + cells (Fig. 3B, middle) . In a separate
Research. 20 co-transfection experiments, either β-catenin or FOXM1 significantly increased NF-κB-dependent reporter gene transcription in primary CML CD34 + cells (Fig. 3B,   right) .
In contrast, co-transfection experiments with p65 siRNA duplexes in combination with constructs of Luc-FOXM1 promoter and pEFRRenilla-Luc showed that p65 knockdown significantly decreased the transcription of FOXM1 in primary CML CD34 + cells (Fig. 3C, left) . Co-transfection of constructs of pTOPflash (or pFOPflash)
and pEFRRenilla-Luc in combination with p65 siRNA duplexes revealed that p65
remarkably decreased the TCF/LEF-dependent transcription in primary CML CD34 + cells (Fig. 3C, right) . Additionally, FOXM1 knockdown significantly reduced NF-κB-and TCF/LEF-dependent reporter gene transcription in primary CML CD34 + cells (Fig. 3D) . Similarly, β-catenin knockdown significantly decreased NF-κB-dependent reporter gene transcription and Luc-FOXM1 promoter transcriptional activity in primary CML CD34 + cells (Fig. 3E ).
Next, we evaluated the effect of niclosamide on NF-κB and β-catenin in primary CML CD34 + cells. The purified CML CD34 + cells were incubated with control or niclosamide±imatinib for 24 h, levels of p65, FOXM1, and β-catenin were detected by IB. The results showed that niclosamide alone or combined with imatinib elicited a robust suppression in FOXM1 and p65 levels (Fig. 3F) . Further, niclosamide decreased levels of p65, FOXM1 and β-catenin by immunofluorescence staining examination (Fig. 3G ).
Taken together, these results suggest that the positive feedback loop formed by
Research. Fig. 4B and C) .
We further quantify the frequency of CML LSCs with limiting dilution LTC-IC assay. Niclosamide reduced the frequency from 1/104 (control) to 1/457 (niclosamide).
Combined niclosamide with imatinib substantially reduced the LT-HSC frequency to a greater degree (Fig. 4D and Supplementary Table S3 ). Therefore, niclosamide alone or combinational treatments between niclosamide and imatinib inhibited the self-renewal capacity of CML LSCs and reduced the CML LT-HSC frequency.
Research. 22 
Niclosamide abolishes the long-term engraftment of CML CD34 + cells in NOG mice
To evaluate the long-term ex vivo effect of niclosamide on survival of CML CD34 + cells, purified human CML CD34 + cells were exposed to niclosamide, then intravenously injected into NOG mice (Fig. 5A) . 
p-Niclosamide significantly prolongs the survival of CML mice and reduces the frequency of LSCs in vivo
To investigate the in vivo effect of niclosamide on CML LSCs, we used a human BCR-ABL gene-driven CML mouse model (27) . The CML mice were treated with placebo, parenteral p-niclosamide, imatinib, and the combination for 2 weeks (Fig.   6A ). p-Niclosamide alone or in combination with imatinib significantly prolonged the overall survival of CML mice as compared with the placebo group (Fig. 6B) 23 were greatly reduced in the mice receiving p-niclosamide or imatinib, and was further reduced in the mice receiving combinational treatment (Fig. 6C) . CML mice receiving p-niclosamide, imatinib, or the combination showed reduction in size and nodule in spleen than those in placebo group (Supplementary Fig. S4A ). Pathology of lungs revealed decreased infiltration of leukemic cells in the CML mice receiving p-niclosamide, imatinib, or the combination (Supplementary Fig. S4B ). 
Aberrant overexpression of NF-κB, FOXM1, and β-catenin in LSCs
Oncogene activation in LSCs may cause NF-κB pathway activation (15, 29) .
LSCs may also produce autocrine TNFα to support their own survival via the NF-κB pathway because increased TNFα was detected in the serum of CML patients (15) .
We discovered aberrant overexpression of intracellular FOXM1, β-catenin, and NF-κB in human CML primitive CD34 + cells as compared with NBM CD34 + cells.
The differential expression may offer a rationale to target LSCs.
Regulatory loop and its significance for LSCs
FOXM1 is widely overexpressed in human tumors, and plays a critical role in cell cycle, DNA replication, mitosis and genomic stability (16) . The association of FOXM1 and β-catenin hints that FOXM1 may be involved in the regulation of self-renewal of CSCs. FOXM1 is essential for the maintenance of HSCs (30) .
Mechanistically, loss of FOXM1 downregulates cyclin-dependent kinase inhibitors (e.g., p21, p27) by directly suppressing the expression of the gene encoding NURR1 (30) . Given that LSCs share properties with normal HSCs, FOXM1 might control Although the interplay of p65 and β-catenin is controversial, more studies have supported a cooperative contribution of NF-κB and β-catenin in tumorigenesis and metastasis (31, 32) . Simultaneous activation of both β-catenin and NF-κB signaling pathways but neither alone is required for the enhanced CSC phenotypes (33) . These findings support a connection between NF-κB and β-catenin. Concordantly, reports have shown the complex crosstalk between NF-κB and WNT/β-catenin in a mouse model of smoke-induced inflammation with lung cancer growth (32) . Mice lacking myeloid RelA/p65 displayed tumor growth delay on inhibition of the WNT/β-catenin pathway (34) . Our findings provide a mechanistic explanation for such a connection.
We found that NF-κB also positively regulates β-catenin by increasing its protein level. NF-κB may increase β-catenin protein stability because we found that pharmacologic inhibition of NF-κB by niclosamide increased ubiquitin-mediated degradation of β-catenin. 
Pharmacological disruption of the p65/FOXM1/β-catenin regulatory loop
Niclosamide has been an oral anthelmintic drug used to treat tapeworms for approximately 50 years (17) . Recent studies from different groups including us have independently shown that niclosamide is effective against CSCs in acute myeloid leukemia, ovarian carcinoma, breast cancer, glioblastoma and colon cancer (36) (37) (38) (39) .
Research. 
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The underlying mechanisms may involve inactivation of pathways of NF-κB and WNT/β-catenin and increased ROS production in CSCs (17, 37, 40, 41) . Niclosamide lowers the levels of Dishevelled-2 (DVL2) and LRP6, components of the WNT pathway (40, 41) . Inhibition of NF-κB niclosamide involves Tak1 and IKK in the NF-κB pathway (17) . In the present study, we discovered that niclosamide and its water soluble derivative downregulated, and thereby disrupted the regulatory loop of In short, our findings provide new insight into the self-renewal regulatory network of CML LSCs and offer a rational approach to eliminate LSCs in CML.
These results warrant further clinical study of parenteral p-niclosamide in CML. 
